Vitamin D3 and vitamin K2 are packaged together because they run two halves of the same job. D3 governs how much calcium you absorb; K2 activates the proteins that decide where that calcium ends up. Take more of one without enough of the other and you push on half of a system. That is the whole logic of the pairing — not marketing, just the biochemistry of two fat-soluble vitamins that were separated by the supplement aisle and not by the body.
Key takeaways
- D3 raises calcium absorption — in a controlled crossover study, absorption was 65% higher at a serum 25(OH)D of 86.5 nmol/L than at 50 nmol/L (Heaney 2003).
- K2 activates osteocalcin and matrix Gla-protein, the proteins that bind calcium into bone and keep it out of soft tissue — and 10–40% of them circulate inactive in healthy adults (Theuwissen 2012).
- The K2 form matters as much as the dose: after identical 420 µg doses, MK-4 was undetectable in serum while MK-7 was still measurable at 48 hours (Sato 2012).
- Three years of 180 µg/day MK-7 slowed the age-related decline in bone mineral density and bone strength in a 244-person randomized trial (Knapen 2013).
What D3 actually does with calcium
Vitamin D3’s best-understood job is absorption. Without adequate 25-hydroxyvitamin D — the storage form your blood test measures — a meaningful share of the calcium you swallow passes straight through.
The classic demonstration comes from Robert Heaney’s group at Creighton University. In a randomized crossover experiment, the same 500 mg oral calcium load was absorbed 65% better when participants’ serum 25(OH)D averaged 86.5 nmol/L than when it averaged 50 nmol/L — both values inside the lab reference range (Heaney et al., J Am Coll Nutr, 2003). Being “in range” and absorbing well are not the same thing.
So D3 opens the gate. The question the label rarely answers is what happens to the calcium once it is inside.
What K2 does that D3 cannot
Two of the body’s calcium-handling proteins only work after vitamin K activates them, in a step called carboxylation:
- Osteocalcin, made by bone-building cells, binds calcium into the bone matrix — but only in its carboxylated form.
- Matrix Gla-protein (MGP) is the body’s principal inhibitor of unwanted soft-tissue calcification. Uncarboxylated, it is a bystander.
Here is the part worth reading twice: in healthy adults, 10–40% of circulating osteocalcin and MGP is uncarboxylated — produced, present, and inactive for want of vitamin K. In a randomized dose-response trial, MK-7 at nutritionally realistic doses increased the carboxylation of both proteins (Theuwissen et al., Br J Nutr, 2012). Vitamin D actually increases the production of these K-dependent proteins, which is the mechanistic heart of the pairing: more D means more proteins waiting on K (van Ballegooijen et al., Int J Endocrinol, 2017).
That is why the two appear in one capsule. D3 without K2 raises the calcium supply and the inactive-protein pool at the same time. Together, the system runs the way the physiology textbooks draw it.
MK-7 vs MK-4: the form question, again
If you read our piece on magnesium forms, you already know the house obsession: the form on the label changes what the body receives. Vitamin K2 has its own version of this. Two forms dominate the supplement market — MK-4 (short side-chain) and MK-7 (long side-chain) — and they behave very differently after you swallow them.
In a head-to-head study in healthy women, a single 420 µg dose of MK-4 was not detectable in serum at any time point. The identical dose of MK-7 was well absorbed and still measurable 48 hours later (Sato et al., Nutr J, 2012). Earlier pharmacokinetic work comparing MK-7 with vitamin K1 found the same signature: similar peak, but a far longer half-life, letting MK-7 accumulate to 7–8× higher steady-state levels with daily intake and drive more complete osteocalcin carboxylation (Schurgers et al., Blood, 2007).
MK-7’s long residence time is not a trivial convenience. A once-daily dose holds serum levels steady around the clock, which is precisely what you want for a vitamin whose job is continuous protein activation.
What the long-term trial showed
The most demanding test of low-dose MK-7 to date is a three-year, double-blind, randomized trial in 244 healthy postmenopausal women taking 180 µg/day. MK-7 improved vitamin K status, slowed the age-related decline in bone mineral content and density at the lumbar spine and femoral neck, and favorably affected bone strength indices (Knapen et al., Osteoporos Int, 2013). The carboxylation markers moved first; the structural measures followed over years, which is how bone works — slowly, in the direction the activated proteins push it.
Note the honest print: this was 180 µg daily for three years in one population. It is support for the mechanism, not a promise, and bone responds to training, protein, and total diet at least as much as to any capsule.
How to read a D3 + K2 label
Applying the house method — read the panel, not the front — four things tell you whether a combination product is serious:
| Check | What to look for | Why |
|---|---|---|
| D3 form | Cholecalciferol, dose in mcg and IU | D3 is the form made in skin; 25 mcg = 1,000 IU |
| K2 form | MK-7 named explicitly | “Vitamin K2” alone can hide MK-4, which a single daily dose may not sustain (Sato 2012) |
| K2 dose | 90–180 µg range | The range where carboxylation measurably improves (Theuwissen 2012; Knapen 2013) |
| Fat-solubility handled | Take with a meal; absorption enhancers declared | Both vitamins are fat-soluble |
Our own Vitamin K2 + D3 is the worked example: one veggie capsule carries 125 mcg (5,000 IU) D3 as cholecalciferol with 100 mcg K2 explicitly as MK-7, plus 210 mg calcium and 5 mg BioPerine®, with every batch third-party tested and its certificate of analysis published. The label states the forms because the forms are the argument.
Frequently asked questions
Can I take D3 without K2?
You can — D3 on its own reliably raises 25(OH)D and calcium absorption. The case for pairing is mechanistic: higher vitamin D status increases production of the K-dependent proteins, so demand for vitamin K rises with your D intake (van Ballegooijen 2017). The pairing simply keeps both halves of the calcium system supplied.
Is MK-7 better than MK-4?
At typical once-daily supplement doses, MK-7 has the pharmacokinetic advantage: measurable in serum for days rather than hours, building 7–8× higher steady-state levels (Schurgers 2007; Sato 2012). MK-4 has its own research history at much higher, multi-dose regimens — a different product category than a daily capsule.
How much K2 do studies use?
Carboxylation of osteocalcin and MGP improved at doses around 90–180 µg/day of MK-7 (Theuwissen 2012), and the three-year bone trial used 180 µg/day (Knapen 2013). Most quality combination products sit in that window.
Why is calcium in the capsule too?
A modest calcium co-dose (ours is 210 mg, 15% DV) gives the absorption machinery a substrate without displacing dietary calcium — most people should still get the bulk of their calcium from food.
The bottom line
D3 decides how much calcium comes in. K2 — as MK-7, at a dose the carboxylation studies actually used — decides whether the proteins that place that calcium are switched on. One capsule, two switches, both halves of the system covered. That is why they are packaged together.
References
- Heaney RP, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22(2):142-6. PMID 12672710 · DOI
- Theuwissen E, et al. Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status. Br J Nutr. 2012;108(9):1652-7. PMID 22289649 · DOI
- Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012;11:93. PMID 23140417 · DOI
- Schurgers LJ, et al. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109(8):3279-83. PMID 17158229 · DOI
- Knapen MHJ, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-507. PMID 23525894 · DOI
- van Ballegooijen AJ, et al. The synergistic interplay between vitamins D and K for bone health: a narrative review. Int J Endocrinol. 2017;2017:7454376. PMID 29138634 · DOI
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Citations describe published research on nutrient physiology; individual results vary, and supplements complement — never replace — a varied diet.
The Journal
Label literacy, one article at a time.
Evidence-checked pieces on forms, doses, and how to read a panel. No hype, unsubscribe anytime.

Leave a Reply